Molecular targeted therapies for patients with refractory thyroid cancer

C. Chougnet; M. Brassard; S. Leboulleux; E. Baudin; M. Schlumberger

doi:10.1016/j.clon.2010.04.008

Molecular targeted therapies for patients with refractory thyroid cancer

C. Chougnet, M. Brassard, S. Leboulleux, E. Baudin, M. Schlumberger

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.

Original language	English
Pages (from-to)	448-455
Number of pages	8
Journal	Clinical Oncology
Volume	22
Issue number	6
DOIs	https://doi.org/10.1016/j.clon.2010.04.008
Publication status	Published - 1 Aug 2010

Keywords

Refractory thyroid cancer
Targeted therapy

Access to Document

10.1016/j.clon.2010.04.008

Cite this

@article{b4bc5a95250f4d6e82e2edbe1796750f,

title = "Molecular targeted therapies for patients with refractory thyroid cancer",

abstract = "The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.",

keywords = "Refractory thyroid cancer, Targeted therapy",

author = "C. Chougnet and M. Brassard and S. Leboulleux and E. Baudin and M. Schlumberger",

year = "2010",

month = aug,

day = "1",

doi = "10.1016/j.clon.2010.04.008",

language = "English",

volume = "22",

pages = "448--455",

journal = "Clinical Oncology",

issn = "0936-6555",

number = "6",

}

TY - JOUR

T1 - Molecular targeted therapies for patients with refractory thyroid cancer

AU - Chougnet, C.

AU - Brassard, M.

AU - Leboulleux, S.

AU - Baudin, E.

AU - Schlumberger, M.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.

AB - The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.

KW - Refractory thyroid cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77954759078&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2010.04.008

DO - 10.1016/j.clon.2010.04.008

M3 - Article

C2 - 20554167

AN - SCOPUS:77954759078

SN - 0936-6555

VL - 22

SP - 448

EP - 455

JO - Clinical Oncology

JF - Clinical Oncology

IS - 6

ER -

Molecular targeted therapies for patients with refractory thyroid cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this